Loading...
Docoh

306 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-99.1
GOVX Geovax Labs Inc
4 Aug 22
GeoVax Reports 2022 Second Quarter Financial Results
4:06pm
(NCT03754933) evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC
424B3
GOVX Geovax Labs Inc
3 Aug 22
Prospectus supplement
4:36pm
of which are summarized below: GEO-CM04S1 is currently undergoing a Phase 2 clinical trial (NCT04977024), evaluating its safety and efficacy … Securities None. Item 4 Mine Safety Disclosures Not applicable. Item 5 Other Information During the period covered by this report
424B3
GOVX Geovax Labs Inc
3 Aug 22
Prospectus supplement
4:35pm
of which are summarized below: GEO-CM04S1 is currently undergoing a Phase 2 clinical trial (NCT04977024), evaluating its safety and efficacy … Securities None. Item 4 Mine Safety Disclosures Not applicable. Item 5 Other Information During the period covered by this report
424B3
GOVX Geovax Labs Inc
3 Aug 22
Prospectus supplement
4:34pm
of which are summarized below: GEO-CM04S1 is currently undergoing a Phase 2 clinical trial (NCT04977024), evaluating its safety and efficacy … Securities None. Item 4 Mine Safety Disclosures Not applicable. Item 5 Other Information During the period covered by this report
10-Q
2022 Q2
GOVX Geovax Labs Inc
3 Aug 22
Quarterly report
4:31pm
significant of which are summarized below: GEO-CM04S1 is currently undergoing a Phase 2 clinical trial (NCT04977024), evaluating its safety and efficacy … Senior Securities None. Item 4 Mine Safety Disclosures Not applicable. Item 5 Other Information During the period covered by this report
424B3
ubzff7q 4897dd9
27 Jun 22
Prospectus supplement
9:13am
S-1
1csdkao2wvjgkw
14 Jun 22
IPO registration
4:03pm
DEF 14A
tyfs8etm8jek
13 Jun 22
Definitive proxy
4:57pm
PRE 14A
ykrlw2
27 May 22
Preliminary proxy
5:07pm
8-K
EX-10.5
3n8v1zinp
27 May 22
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
4:48pm
8-K
EX-10.1
eujp3wvbukzm6e1
27 May 22
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
4:48pm
424B5
tehrrcqe6kxtnx1w9
27 May 22
Prospectus supplement for primary offering
8:49am
8-K
EX-99.1
e5u5yvhu546u697
2 May 22
GeoVax Reports 2022 First Quarter Financial Results
7:30am
8-K
EX-99.2
yv35o cvm1jro
2 May 22
GeoVax Reports 2022 First Quarter Financial Results
7:30am
424B3
e1qx1us8
27 Apr 22
Prospectus supplement
4:06pm
424B3
89l lsykv
27 Apr 22
Prospectus supplement
4:05pm
10-K/A
haii79ai
27 Apr 22
Annual report (amended)
4:03pm
10-Q
k7c9nt7rebdpfn
27 Apr 22
Quarterly report
4:00pm
8-K
EX-99.2
etvcrhgwlsefgsh
10 Mar 22
GeoVax Reports 2021 Year-End Financial Results
5:02pm
8-K
EX-99.1
5uajz eq12emjyc5rmu2
10 Mar 22
GeoVax Reports 2021 Year-End Financial Results
5:02pm